title: Protective role of misoprostol against cisplatin-induced ototoxicity.
abstract: Cis-diammineedichloroplatinum (cisplatin) is a chemotherapeutic agent that is widely used in the treatment of many cancers. Nephrotoxicity, ototoxicity and neurotoxicity are dose-limiting adverse effects for cisplatin. The cellular and molecular mechanisms underlying cisplatin-induced ototoxicity aren't fully understood. It has been proposed that cisplatin primarily cause damage at the cochlea, outer hair cells in particular, leading to excessive production of free oxygen radicals in the organ of Corti, stria vascularis, spiral ligament, and spiral ganglionic cells. The cytotoxicity is associated with the generation of reactive oxygen species (ROS); thus, there is an increasing interest on antioxidants with an effort to discover the established protection against cisplatin-induced ototoxicity over time. Misoprostol (MP) has gained considerable interest as a reactive oxygen species scavenger in recent years. To best of our knowledge, there is no study about protective effect of MP, a prostaglandin E1 (PGE1) analogue, on cisplatin-induced ototoxicity. In our study, we show that protective effects of misoprostol on cisplatin-induced ototoxcity on rats.
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey. drmdogan@hotmail.com.|Kayseri Eğitim ve Araştırma Hastanesi KBB Kliniği Sanayi Mah. Atatürk Bulvarı Hastane Cad. No: 78 38010, Kayseri, Turkey. drmdogan@hotmail.com.
authors.forename: Murat
authors.initials: M
authors.lastname: Doğan
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Halil
authors.initials: H
authors.lastname: Polat
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yaşar
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Altan
authors.initials: A
authors.lastname: Kaya
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Bayram
authors.affiliation: Department of Pathology, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Fatma
authors.initials: F
authors.lastname: Şenel
authors.affiliation: Department of ENT, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Özcan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D016595:Misoprostol / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D020011:Protective Agents; D016595:Misoprostol; D002945:Cisplatin
keywords: Cisplatin; Misoprostol; Otoacoustic emission; Ototoxcity; Rat